{"id":"acipimox","rwe":[],"tags":[{"label":"acipimox","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Hydroxycarboxylic acid receptor 2","category":"target"},{"label":"HCAR2","category":"gene"},{"label":"C10AD06","category":"atc"},{"label":"Active","category":"status"},{"label":"Hyperlipoproteinemia","category":"indication"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Hypolipidemic Agents","category":"pharmacology"},{"label":"Lipid Regulating Agents","category":"pharmacology"}],"phase":"phase_3","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"olbemox","offLabel":[],"synonyms":["acipimox","olbemox","olbetam","methylpyrazinecarboxylic acid 4-oxide"],"timeline":[],"brandName":"Olbemox","ecosystem":[{"indication":"Hyperlipoproteinemia","otherDrugs":[],"globalPrevalence":4000000}],"mechanism":{"target":"Hydroxycarboxylic acid receptor 2","targets":[{"gene":"HCAR2","source":"DrugCentral","target":"Hydroxycarboxylic acid receptor 2","protein":"Hydroxycarboxylic acid receptor 2"}],"modality":"Small Molecule","drugClass":"acipimox","explanation":"Think of it like a key that unlocks a process in the liver. When activated, the hydroxycarboxylic acid receptor 2 helps to slow down the production of triglycerides, which are a type of fat that can build up in the blood and increase the risk of heart disease. This can help to lower cholesterol levels and improve overall heart health.","oneSentence":"Olbemox works by activating the hydroxycarboxylic acid receptor 2, which helps to reduce the production of triglycerides in the liver.","technicalDetail":"Olbemox acts as a potent agonist of the hydroxycarboxylic acid receptor 2 (HCAR2), a nuclear receptor that regulates the expression of genes involved in lipid metabolism, particularly the breakdown of triglycerides in the liver."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/76","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ACIPIMOX","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACIPIMOX","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:25:13.134476","biosimilars":[],"competitors":[{"drugName":"nicotinic acid","drugSlug":"nicotinic-acid","fdaApproval":"1957-07-24","relationship":"same-class"}],"genericName":"acipimox","indications":{"approved":[{"name":"Hyperlipoproteinemia","source":"DrugCentral","snomedId":3744001,"regulator":"FDA","usPrevalence":null,"globalPrevalence":4000000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"nicotinic-acid","brandName":"nicotinic acid","genericName":"nicotinic acid","approvalYear":"1957","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06229678","phase":"EARLY_PHASE1","title":"Ketones, SGLT2, HFrEF","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-01-25","conditions":["Type2diabetes","Heart Failure With Reduced Ejection Fraction"],"enrollment":71,"completionDate":"2027-03-01"},{"nctId":"NCT03338387","phase":"PHASE2","title":"Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia","status":"ENROLLING_BY_INVITATION","sponsor":"Charles University, Czech Republic","startDate":"2003-05-06","conditions":["Eating Disorder","Bulimia Nervosa"],"enrollment":24,"completionDate":"2026-12-20"},{"nctId":"NCT03866512","phase":"NA","title":"Forearm Immobilization, Metabolic Health, and Muscle Loss","status":"COMPLETED","sponsor":"University of Exeter","startDate":"2019-05-10","conditions":["Healthy"],"enrollment":37,"completionDate":"2021-07-01"},{"nctId":"NCT06317142","phase":"","title":"Glucose and Glycogen Dynamics in Prediabetes","status":"RECRUITING","sponsor":"Maastricht University Medical Center","startDate":"2024-02-20","conditions":["Pre Diabetes"],"enrollment":45,"completionDate":"2025-07"},{"nctId":"NCT03804892","phase":"NA","title":"Can Brisk Walking Combined With Ingestion of a Lipid-lowering Drug Improve Fat Metabolism in Muscle?","status":"UNKNOWN","sponsor":"Liverpool John Moores University","startDate":"2019-10-01","conditions":["Pre Diabetes"],"enrollment":12,"completionDate":"2024-12"},{"nctId":"NCT03809793","phase":"NA","title":"Can the Health Benefits of a Walking-based Exercise Programme be Enhanced by Co-ingestion of a Lipid-lowering Drug?","status":"COMPLETED","sponsor":"Liverpool John Moores University","startDate":"2020-01-06","conditions":["Pre-diabetes"],"enrollment":15,"completionDate":"2023-07-31"},{"nctId":"NCT00759291","phase":"PHASE2,PHASE3","title":"The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2006-04-01","conditions":["Metabolic Syndrome"],"enrollment":40,"completionDate":"2017-12-30"},{"nctId":"NCT01816165","phase":"PHASE3","title":"Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2011-06","conditions":["Type 1 Diabetes"],"enrollment":28,"completionDate":"2015-06-24"},{"nctId":"NCT01580813","phase":"NA","title":"Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2011-06","conditions":["Type 2 Diabetes"],"enrollment":13,"completionDate":"2015-06-05"},{"nctId":"NCT02782208","phase":"NA","title":"Lipolytic Effects of GH in Hypopituitary Patients in Vivo","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2016-02-10","conditions":["Hypopituitarism","Insulin Resistance","Endocrine System Diseases","Glucose Metabolism Disorders","Metabolic Diseases","Pituitary Diseases","Brain Diseases"],"enrollment":9,"completionDate":"2016-12-22"},{"nctId":"NCT02792621","phase":"NA","title":"Increasing Mitochondrial Function on Skeletal Muscle Performance in Older Men","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2016-11-08","conditions":["Impaired Mitochondrial Function, Muscle Performance"],"enrollment":16,"completionDate":"2019-12-15"},{"nctId":"NCT03325491","phase":"NA","title":"Assessing the Effects of Increased Mitochondrial Function Exercise Training on Muscle Performance","status":"TERMINATED","sponsor":"University of Exeter","startDate":"2018-03-07","conditions":["Impaired Mitochondrial Function, Muscle Performance"],"enrollment":2,"completionDate":"2019-09-16"},{"nctId":"NCT00153179","phase":"PHASE1,PHASE2","title":"Free Fatty Acids and Vascular Function in Subjects With Diabetes","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2005-09","conditions":["Type 2 Diabetes Mellitus"],"enrollment":40,"completionDate":"2013-03"},{"nctId":"NCT02796950","phase":"NA","title":"The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2016-06","conditions":["Diabetes Mellitus Type 2"],"enrollment":8,"completionDate":"2017-01-20"},{"nctId":"NCT01209416","phase":"NA","title":"The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2012-06","conditions":["Metabolism","Insulin Resistance","Hypopituitarism"],"enrollment":8,"completionDate":"2015-10"},{"nctId":"NCT01980524","phase":"PHASE2,PHASE3","title":"The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2013-10","conditions":["Type 2 Diabetes"],"enrollment":8,"completionDate":"2016-05"},{"nctId":"NCT01488409","phase":"PHASE2","title":"Effects of Acipimox on Mitochondrial Function in Obesity","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-05","conditions":["Abdominal Obesity","Insulin Resistance","Hypertriglyceridemia"],"enrollment":39,"completionDate":"2015-01"},{"nctId":"NCT01752348","phase":"NA","title":"Effects of Free Fatty Acids and 3-hydroxybutyrate on Protein, Glucose, Lipid Metabolism and Intracellular Signals.","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2013-02","conditions":["Systemic Inflammatory Response Syndrome"],"enrollment":10,"completionDate":"2014-11"},{"nctId":"NCT02256722","phase":"PHASE1","title":"In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-10","conditions":["Healthy"],"enrollment":12,"completionDate":""},{"nctId":"NCT01299831","phase":"NA","title":"The Relationship Between Body Composition and Growth Hormone, SIRT Signaling, Protein Turnover and Insulin Sensitivity","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2011-01","conditions":["Healthy"],"enrollment":19,"completionDate":"2013-12"},{"nctId":"NCT00246402","phase":"NA","title":"Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2002-09","conditions":["Insulin Resistance","Cardiovascular Diseases","Heart Diseases","HIV Infections","Hypertriglyceridemia","Hyperlipidemia"],"enrollment":30,"completionDate":"2006-08"},{"nctId":"NCT00943059","phase":"NA","title":"Cross-over Study on Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2010-03","conditions":["Diabetes Mellitus, Type 2","Cardiomyopathy, Dilated"],"enrollment":31,"completionDate":"2012-12"},{"nctId":"NCT01260376","phase":"NA","title":"Effect of Pharmacological Anti-lipolysis on FFA and VLDL-TG Metabolism Before and During Exercise","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2011-04","conditions":["Diabetes","Obesity"],"enrollment":9,"completionDate":"2012-09"},{"nctId":"NCT00549614","phase":"NA","title":"Effect of 4 Weeks Treatment With Acipimox in Patients With Chronic Heart Failure","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2007-10","conditions":["Heart Failure"],"enrollment":28,"completionDate":"2009-05"},{"nctId":"NCT00449423","phase":"PHASE2","title":"Metabolic Modulation as Treatment in Acute Heart Failure","status":"TERMINATED","sponsor":"University of Aarhus","startDate":"2007-03","conditions":["Acute Heart Failure"],"enrollment":32,"completionDate":"2007-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"003918","UNII":"K9AY9IR2SD","CHEBI":"CHEBI:94688","INN_ID":"3809","RXNORM":"16817","UMLSCUI":"C0050558","ChEMBL_ID":"CHEMBL345714","KEGG_DRUG":"D07190","DRUGBANK_ID":"DB09055","PUBCHEM_CID":"5310993","SNOMEDCT_US":"319982006","IUPHAR_LIGAND_ID":"1596","MESH_SUPPLEMENTAL_RECORD_UI":"C027696"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"90%"},"publicationCount":333,"therapeuticAreas":["Gastroenterology"],"atcClassification":{"source":"DrugCentral","atcCode":"C10AD06","allCodes":["C10AD06"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olbemox is a small molecule with an unknown mechanism of action. It has been studied in clinical trials for conditions such as hypopituitarism, insulin resistance, and metabolic diseases, and has been compared to acipimox and placebo in these studies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}